Trial Profile
Carfilzomib, Lenalidomide and Dexamethasone versus Lenalidomide and Dexamethasone in High- Risk Smoldering Multiple Myeloma: A Randomized Phase II Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Mar 2024
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Smoldering multiple myeloma
- Focus Therapeutic Use
- Acronyms HOVON 147 SMM-EMN15
- 21 Mar 2024 This trial has been completed in Czechia, according to European Clinical Trials Database record.
- 08 Mar 2024 This trial has been Discontinued in Italy according to European Clinical Trials Database record.
- 31 Oct 2023 Planned End Date changed from 1 Oct 2025 to 1 Dec 2028.